<SEC-DOCUMENT>0001628280-17-000328.txt : 20170120
<SEC-HEADER>0001628280-17-000328.hdr.sgml : 20170120
<ACCEPTANCE-DATETIME>20170120170034
ACCESSION NUMBER:		0001628280-17-000328
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170120
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE:		20170120
DATE AS OF CHANGE:		20170120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		17539108

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k-boardappointment.htm
<DESCRIPTION>8-K - BOARD APPOINTMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s89219f6cbc004d79bedc09b2ebc7a273"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:51%;"></td><td style="width:5%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 20, 2017 (January 16, 2017)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:0%;"></td><td style="width:33%;"></td><td style="width:18%;"></td><td style="width:5%;"></td><td style="width:11%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.</font></div><div style="line-height:120%;padding-top:15px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On January 16, 2017, Cumberland Pharmaceuticals Inc. (the "Company") announced the addition of Kenneth J. Krogulski, CFA to its Board of Directors. Kenneth is the President and Chief Executive Officer of </font><font style="font-family:inherit;font-size:11pt;font-style:italic;">Berkshire Asset Management LLC </font><font style="font-family:inherit;font-size:11pt;">("Berkshire"). He is also the Chief Investment Officer of Berkshire, a 30-year-old independent SEC registered investment advisory firm with over $1.5 billion under management. Kenneth's appointment to Cumberland's Board was effective January 18, 2017.</font></div><div style="line-height:120%;padding-top:15px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Kenneth has over 37 years' experience in security analysis and portfolio management. He began his career in finance at First Eastern Bank (now PNC Financial) as an investment analysis and portfolio manager. He then served as senior portfolio manager in First Eastern's trust department. Mr. Krogulski then joined Berkshire and later led a management buy-out acquiring the company from Legg Mason. Under his leadership, Berkshire's assets under supervision have grown from $600 million in 2006 and are now over $1.5 billion.</font></div><div style="line-height:120%;padding-top:15px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Kenneth earned his B.S. in finance from Indiana University of Pennsylvania and his M.B.A from Wilkes University. He holds the Chartered Financial Analysts designation. </font></div><div style="line-height:120%;padding-top:15px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:168px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:68%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">January 20, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:15px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a8k-pressreleasexboardappo.htm
<DESCRIPTION>EXHIBIT 99.1 - 8K PRESS RELEASE BOARD APPOINTMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s85c39341d6fe424ab59c745f024cae49"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;"><img src="cumberlanda01.gif" alt="cumberlanda01.gif" style="height:85px;width:374px;"></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS ANNOUNCES</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">KENNETH J. KROGULSKI TO JOIN ITS BOARD OF DIRECTORS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tenn., January 16, 2017</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) </font><font style="font-family:inherit;font-size:12pt;">is pleased to announce the addition of Kenneth J. Krogulski, CFA to its Board of Directors. He is the President and Chief Executive Officer of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Berkshire Asset Management LLC</font><font style="font-family:inherit;font-size:12pt;">.  He is also the Chief Investment Officer of Berkshire, a 30-year-old independent SEC registered investment advisory firm with over $1.5 billion under management.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mr. Krogulski has over 37 years&#8217; experience in security analysis and portfolio management. He began his career in finance at First Eastern Bank (now PNC Financial) as an investment analysis and portfolio manager. He then served as senior portfolio manager in First Eastern&#8217;s trust department. Mr. Krogulski then joined Berkshire and later led a management buy-out acquiring the company from Legg Mason. Under his leadership, Berkshire&#8217;s assets under supervision have grown from $600 million in 2006 and are now over $1.5 billion.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">He earned his B.S. in finance from Indiana University of Pennsylvania and his M.B.A from Wilkes University. He holds the Chartered Financial Analysts designation. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Ken adds a new perspective to our Board, given his role and experience as an investor and portfolio manager,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We look forward to working with him as we seek to elevate Cumberland&#8217;s public company profile.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;I am impressed with Cumberland&#8217;s proven management team, strong fundamentals and growing portfolio of specialty branded pharmaceuticals,&#8221; said Ken Krogulski. &#8220;I look forward to working with the team at Cumberland to advance the Company&#8217;s mission of enhancing patient care, while also building significant shareholder value.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mr. Krogulski&#8217;s appointment to Cumberland&#8217;s Board as an independent director will be effective January 18, 2017. Cumberland&#8217;s Board of Directors also includes Joey Jacobs, Chairman and CEO of Acadia Healthcare, Dr. Gordon Bernard, Associate Vice-Chancellor for Research atVanderbilt University Medical Center, Jamie Jones, former Managing Partner of KPMG LLP&#8217;s Middle Tennessee operations, Thomas Lawrence, Chairman of Aetos Technologies, Jon Griggs, Former Vice President at Warner-Lambert Company, and Caroline Young, former President of the Nashville Healthcare Council, who also all serve as independent directors.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cumberland Pharmaceuticals </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquisition, development, and commercialization of high-quality products that improve the quality of care for patients. The Company has a diverse product portfolio with a focus in the areas of hospital acute care and gastroenterology. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of hyponatremia, Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;for the treatment of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;and duodenal ulcer disease, and Ethyol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(amifostine) for Injection, for the prevention of treatment-related adverse reactions in oncology patients.  Cumberland is also dedicated to developing innovative products that address unmet medical needs. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company&#8217;s product candidates in clinical development include: Hepatoren</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of hepatorenal syndrome, Boxaban</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Oral Capsule for patients suffering from aspirin exacerbated respiratory disease, Vasculan</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">TM</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Oral Capsule for the treatment of systemic sclerosis and Portaban&#8482; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Oral Capsule for the treatment of portal hypertension. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information on Cumberland Pharmaceuticals Inc., please visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Investor Contact:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Erin Smith</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">615-255-0068</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">investors@cumberlandpharma.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Media Contact:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rebecca Kirkham</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lovell Communications</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">615-297-7766</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">rebecca@lovell.com</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlanda01.gif
<TEXT>
begin 644 cumberlanda01.gif
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M.N0GG3[<XBNI?IO?*;G>*7.FMVZ[2K)#"3OK:/%-%8/E)GF=9YY5![(//C0
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M)R.J$RZ:!BN_@A.7I=PUV7G!5[(O(ZY(JV7*/+*E.&)<Z'2B0U-6/LD'UG6
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ME2^9>,>YLYK0/  (_MQN &PB]#LJV-LD#!AXQ2].C2F8) 0]X-P!0D"2+/M
M ]"KH (.,(4Y/[E3J6ASM:O]9C=S8!I0U\<!R! MEP2!'P8X1=;W88!]<-WK
M!A  UT\A]GW3!0("$$ ">J#3#9!= %/J']K3SH/(A*0  @B[ #8@K#&D_>M>
M!WS7 Y_U1@5;*P7 >M?#/OC&@WT?9!\55_ ^=LCO(^^6)_SE3\%WM?0C5 (
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M *<P!H!P@W"7+X82@R@G@>*',"'A=_Q7$L7(%6C3D0^0BA+H!=/A!=+H %0
M!!L@#S"Y0R+Q "-##=FX$HC&3%<(9VYV;>C89J3@?>U("M?V ZE -"#D$:&8
M #18$O(0*@G  PO&A*X'DB6Q 7I'>PPR=U20B!<80#R0=QK0@ !W*LSXBE59
M$@[@>I6(%?48<<T!')0G?R$1E-JQ?TD( "9)D=%E7^I"@@$)D )0B?_"%7;)
M=8E9>+ZX-6/0=7$7;5Q!E*=PF"5!B ; #[37#\='#1MP  6 E.1!*&CA  A@
M#S4B%Y9"4.)PCLK9_Y73\'0_ '7>]V8'\ -30%,R-649Z'HT^(L>P3G/-Q(
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MRZ&WXV[SEVKWGZV7[.2;TWT]>R;QRST/=JXG]*'' )\HB&6=*IM1'2R%"E,
M =2B:VKA7_E9AO(&WM %$EBN%QC2 Y\#!+ZD"PCP^(Y?;KXD?%Q/W%3@2XS/
M^)#_^)D_!L*7V#JM+1I@W;$Q!4#  PB D2%!;H_?^K[T^)B/^9#*GXUJ;K'O
M^IH_^0APNA@HB:=;&H]S'4M9;@B0_Y.2,SV1K_F=KRV;+]A0K"V3?K2M<:SF
M9JE^6FY 8/Q0@C:2" 08^+JVS_FWO_N0FL8M<1I+3B^BG H'H/?*3>I_;QS
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M^#J0P\8Z LI#K?1Z#\.?M&H.1-,HFH^\@7P0![>Y])/@!_XXF";)$:;11Q\
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M'QO'  0!*/%H&.,E/<S'QU^^#B$%2$ "#C C+T23"FD+S10$D !J.$N634S
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EENT,R5'!1LVO-'5DG#8]));2UFF4$%Y62XV/G4S60/F'@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
